Castle Biosciences: From Dermatology Specialist to Broad Diagnostics Provider

The company is successfully transforming from a pure dermatology niche player to a broadly positioned diagnostics provider, with the new test for esophageal diseases unlocking enormous market potential. Castle Biosciences impresses with very high gross margins and a solid balance sheet, while its operational business is increasingly approaching the profitability threshold. The biggest threat to the stock price remains the dependence on the volatile reimbursement decisions of U.S. health insurers, as negative determinations can directly...